Acumen Pharmaceuticals (ABOS) Q2 2024 earnings summary

Executive summary

• Sabirnetug is a next-generation monoclonal antibody targeting toxic amyloid beta oligomers for early Alzheimer's disease, with positive Phase 1 results and ongoing Phase 2 ALTITUDE-AD and subcutaneous studies; first subject dosed in May 2024 and subcutaneous study initiated in July 2024.

• Presented new biomarker and patient interview data at AAIC 2024, reinforcing sabirnetug's differentiated mechanism of action.

• Acumen holds exclusive global rights to sabirnetug, with strong IP protection and market exclusivity into the 2030s.

• Entered global collaboration with Halozyme for subcutaneous formulation development, aiming to broaden patient access and convenience.

• Virtual R&D Day planned for October 2, 2024, to discuss scientific rationale and clinical plans.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $281.4 million as of June 30, 2024, expected to fund operations into the first half of 2027.

• R&D expenses were $19.5 million for Q2 2024, up year-over-year due to ALTITUDE-AD trial costs.

• G&A expenses reached $4.8 million for Q2 2024, reflecting increased headcount and organizational growth.

• Net loss for Q2 2024 was $20.5 million, up from $11.6 million in Q2 2023.

• Net cash used in operating activities was $34.4 million for the six months ended June 30, 2024.

Outlook and guidance

• Topline results from the Phase 1 subcutaneous sabirnetug study are anticipated in Q1 2025.

• ALTITUDE-AD Phase 2 trial enrollment is progressing rapidly, with completion expected in the first half of 2025.

• Expenses and operating losses are projected to increase as clinical development advances.

• Well-resourced to support ongoing and planned clinical development.